Moreover, the median overall survival of elderly HL patients was significantly inferior compared with a “normal” age- and sex-matched population (26 vs 150 months, respectively; P < .0001). J Clin Oncol 25:3746-3752, 2007. 23. 58. Deaths come from SEER 9 Incidence-Based Mortality. [66] The objective response rate was 22%, with a median response duration of 7.8 months. The GHSG showed that severe toxicity (ie, World Health Organization grade 4) was more common in older patients vs younger patients (42% vs 27%; P < .001). The majority of treatment outcome data are derived from registry data and retrospective reports (Table 2). Among two Swedish population reports from 1979 to 1988[22] and 1973 to 1994,[20] 31% and 26% of all HL patients, respectively, were ≥ 60 years. [47-49] Initial phase I trials of bleomycin suggested an increased risk of bleomycin lung toxicity among elderly patients. [8,9] Intensive treatments such as BEACOPP (bleomycin, etoposide, doxorubicin [Adriamycin], cyclophosphamide, vincristine [Oncovin], procarbazine, and prednisone) are too toxic for older HL patients,[10] while bleomycin-containing regimens including ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) are often poorly tolerated. 60. Exp Toxicol Pathol 53:501-510, 2002. Kim et al reported the outcomes of 52 early-stage patients over a 26-year period (Table 3). Haematologica 92(s5):44, 2007. [1,3-5], Suboptimal staging and inadequate treatment delivery for older patients may compromise the rate of cure. 53. [69] They studied 29 older patients who were treated with CHOP every 21 days (early-stage: 2–4 cycles and IFRT; advanced-stage: 6–8 cycles with or without IFRT). In addition, preclinical data[52,53] and case series[14,54,55] have suggested that granulocyte colony-stimulating factor (G-CSF, Neupogen) may increase the incidence of bleomycin-induced lung damage, related in part to extensive neutrophil recruitment following G-CSF administration, with associated free radical–induced pulmonary damage. Diepstra A, van Imhoff GW, Karim-Kos H, et al: Latent EBV infection of Hodgkin Reed-Sternberg cells predicts adverse outcome in older adult classical Hodgkin lymphoma patients. The older group experienced twice the risk of dying from HL and four times the risk of dying from other causes compared with the younger group. If you would rather reach us by phone, you can call the LLS IRC toll-free line at 1-800-955-4572 from 9am-9pm ET Monday-Friday or send us a message at https://www.lls.org/content/contact-us?UID=LLS-26-756. Acta Oncol 38:425-429, 1999. Death rates, 2013-2017 0.3. Haematologica 79:46-54, 1994. Investigators from the United Kingdom prospectively studied the incidence and outcomes of HL patients diagnosed between 1991 and 1998. Dirix LY, Schrijvers D, Druwe P, et al: Pulmonary toxicity and bleomycin. Schulz H, Rehwald U, Morschhauser F, et al: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). The 3-year survival rate as of January 1, 2015, was 66.3 percent (for all races and ethnicities). 47. Clinical characteristics of elderly HL patients are available through registry databases and some prospective clinical trials. Using statistical models for analysis, age-adjusted rates for new follicular lymphoma cases have been falling on average 1.9% each year over 2008–2017. Prevalence statistics were not reported by SEER for MDS in 2020 at the time of this publication. Within population-based studies, the proportion of HL patients aged 60 years or more has ranged from 15% to 30%. [1] Moreover, EBV-positive HL was associated with an inferior overall survival (median overall survival = 20 months vs not reached, respectively; P = .007). the type of lymphoma; the organs affected; your age and overall health; According to the ACS, the five-year survival rate for stage 4 Hodgkin’s lymphoma is about 65 percent. Blood 86:1493-1501, 1995. The chemotherapy regimens used were heterogeneous with a median of six cycles delivered. However, survival rates for elderly patients with HL (often defined as ≥ 60 years of age) are inferior to those achieved by younger populations. In addition, several sources of evidence suggest a different biology in patients with elderly HL. *The survival rate of CML in clinical trials is higher than the survival rate reported here, based on SEER data. J Clin Oncol 23:5052-5060, 2005. Kolstad and colleagues recently reported encouraging results using CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for elderly HL. Chand VK, Link BK, Ritchie JM, et al: Neutropenia and febrile neutropenia in patients with Hodgkin’s lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. The earlier follicular lymphoma is caught, the better chance a person has of surviving five years after being diagnosed. New cases come from SEER 13. Also, keep in mind that survival rates for different types of non-Hodgkin lymphoma at … It excludes the risk of dying from other causes. Autologous stem cell transplantation for relapsed/refractory HL may be considered for selected older patients with chemotherapy-sensitive disease and good functional status. 1. Cancer Patterns among Asian and Pacific Islanders in the U.S. Additional non-Hodgkin lymphoma survival statistics in SEER*Explorer, Additional statistics on non-Hodgkin lymphoma by stage in SEER*Explorer, Explore Additional Non-Hodgkin Lymphoma Statistics, More about risk factors for non-Hodgkin lymphoma, More about symptoms and diagnosis of non-Hodgkin lymphoma, More about treatment options for non-Hodgkin lymphoma, https://seer.cancer.gov/statfacts/html/follicular.html, Division of Cancer Control and Population Sciences (DCCPS), U.S. Department of Health and Human Services, Mortality statistics for follicular lymphoma are based on. 57. Elderly HL has been aptly described as an orphan disease,[18] defined as a disease that affects fewer than 200,000 persons at a given time. Because lymph tissue is found all through the body, lymphoma can begin almost anywhere. 42. Rates are Age-Adjusted. 27. Boleti E, Mead GM: ABVD for Hodgkin’s lymphoma: Full-dose chemotherapy without dose reductions or growth factors. [46] The complete response rate was lower for patients aged ≥ 60 years, while the relapse rate was similar at 42%, at a median of 21 months (range = 3–165 months). Roy P, Vaughan Hudson G, Vaughan Hudson B, et al: Long-term survival in Hodgkin’s disease patients. In 2020, there are expected to be 85,720 new cases of lymphoma diagnosed in the US (8,480 cases of HL, 77,240 cases of NHL). 18. For the GHSG, Engert et al studied chemotherapy administration differences based on age. Average annual rate per 100,000, age adjusted to the 2000 US standard population. J Clin Oncol 21:607-614, 2003. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas. Unfortunately, as discussed before, it is often difficult to maintain a high/adequate ABVD RDI for elderly patients. 63. Kolstad A, Nome O, Delabie J, et al: Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. [5] Approximately 15% of HL patients in the population were ≥ 65 years, whereas < 5% of patients in the same age group were entered onto BNLI trials. Blood 101:420-424, 2003. Please note, our regular chat hours are Monday-Friday, 10AM to 7PM Eastern Time. 62. [13] These investigators also found frequent mixed cellularity among older patients, while younger patients more commonly presented with bulky mediastinal disease (22% vs 2%, respectively; P < .01). The 5-year event-free survival or freedom from treatment failure rates for elderly HL range from 30% to 40%,[1-4] with 5-year overall survival rates ranging from 40% to 55%. Yarnold JR, Jelliffe AM, Hudson GV: Factors affecting relapse following chemotherapy for Hodgkin’s disease. [32] Of note, only 9% of patients in the study that established the IPS were over 55, and no patients over 65 were included. 7th International Symposium on Hodgkin Lymphoma (abstract I038). The SEER program only recently began maintaining statistics for MDS. Haematologica 92(s5):29, 2007. I am a Patient looking for Disease/Treatment Information related to. 55. Prevalence is the estimated number of people alive on a certain date in a population who previously had a diagnosis of the disease. J Clin Oncol 23:7604-7613, 2005. Cancer 71:1857-1866, 1993. Acta Oncol 41:659-667, 2002. Cancer 98:310-314, 2003. Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. From 2009 to 2015, the five-year relative survival rates overall were, ALL – 71.7 percent overall, 91.9 percent for children and adolescents younger than 15 years, and 94.1 percent for children younger than 5 years, AML – 29.4 percent overall and 68.7 percent for children and adolescents younger than 15 years. Ekstrand BC, Lucas JB, Horwitz SM, et al: Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Erdkamp FL, Breed WP, Bosch LJ, et al: Hodgkin disease in the elderly. 18F-fluorodeoxyglucose (FDG)–positron emission tomography (PET) has become a standard imaging modality for the evaluation of HL. Leuk Lymphoma 47:657-663, 2006. Kim HK, Silver B, Li S, et al: Hodgkin’s disease in elderly patients (> or =60): Clinical outcome and treatment strategies. Click on the links below to view statistics about each disease: With the release of the 1975-2016 Cancer Statistics Review, the calculation of limited-duration prevalence estimates were modified to use data from the SEER 13 areas (not including the Alaska Natives Registry) using cases diagnosed from 1992 through 2015. Rate of New Cases and Deaths per 100,000: The rate of new cases of follicular lymphoma was 2.7 per 100,000 men and women per year. Diepstra et al reported that the lack of HLA class II cell-surface expression on HRS cells was associated with inferior failure-free and overall survival.